The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 301-316

  Mikami, Toshiyuki ^a   Aoki, Mikio ^a   Kimura, Toru ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Biomarker; Body fluids; Drug development; Mass spectrometry; Metabolomics; Pharmaceutical company; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROSPINAL FLUID; DRUG INDUSTRY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; URINE;

EID: 84861759321     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020301     Document Type: Review

References (178)

1. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.; Schacht, A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov., 2010, 9, 203-314.
2. DiMasi, J.A.; The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics, 2002, 20, 1-10.
3. Frank, R.; Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov., 2003, 2, 566-580.
4. Niedbala, R.S.; Mauck, C.; Harrison, P.; Doncel, G.F. Biomarker discovery: validation and decision-making in product development. Sex. Transm. Dis., 2009, 36, S76-80.
5. Kuhlmann, J.; Wensing, G. The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr. Clin. Pharmacol., 2006, 1, 185-191.
6. Wagner, J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 631-651.
7. Colburn, W.A. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol., 2003, 43, 329-341.
8. Woodcock, J. Chutes and ladders on the critical path: comparative effectiveness, product value, and the use of biomarkers in drug development. Clin. Pharmacol. Ther., 2009, 86, 12-14.
9. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
10. Lathia, C.D.; Amakye, D.; Dai, W.; Girman, C.; Madani, S.; Mayne, J.; MacCarthy, P.; Pertel, P.; Seman, L.; Stoch, A.; Tarantino, P.; Webster, C.; Williams, S.; Wagner, J.A. The value, qualification, and regulatory use of surrogate end points in drug development. Clin. Pharmacol. Ther., 2009, 86, 32-43.
11. Goodsaid, F.; Frueh, F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J., 2007, 9, E105-108.
12. Wagner, J.A.; Williams, S.A.; Webster, C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther., 2007, 81, 104-107.
13. Hurko, O. The uses of biomarkers in drug development. Ann. N. Y. Acad. Sci., 2009, 1180, 1-10.
14. Marrer, E.; Dieterle, F. Promises of biomarkers in drug development-a reality check. Chem. Biol. Drug Des., 2007, 69, 381-394.
15. Baker, M. In biomarkers we trust? Nat. Biotechnol., 2005, 23, 297-304.
16. Lee, J.W.; Devanarayan, V.; Barrett, Y.C.; Weiner, R.; Allinson, J.; Fountain, S.; Keller, S.; Weinryb, I.; Green, M.; Duan, L.; Rogers, J.A.; Millham, R.; O'Brien, P.J.; Sailstad, J.; Khan, M.; Ray, C.; Wagner, J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res., 2006, 23, 312-328.
17. Lee, J.W.; Hall, M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877, 1259-1271.
18. Wang, J.; Lee, J.; Burns, D.; Doherty, D.; Brunner, L.; Peterson, M.; DeSilva, B. "Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J., 2009, 11, 385-394.
19. Chau, C.H.; Rixe, O.; McLeod, H.; Figg, W.D. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res., 2008, 14, 5967-5976.
20. Wagner, J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers., 2002, 18, 41-46.
21. Wagner, J.A.; Wright, E.C.; Ennis, M.M.; Prince, M.; Kochan, J.; Nunez, D.J.; Schneider, B.; Wang, M.D.; Chen, Y.; Ghosh, S.; Musser, B.J.; Vassileva, M.T. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin. Pharmacol. Ther., 2009, 86, 619-625.
22. Eck, S.L.; Paul S.M. Biomarker qualification via public-private partnerships. Clin. Pharmacol. Ther., 2010, 87, 21-23.
23. Warnock, D.G.; Peck, C.C. A roadmap for biomarker qualification. Nat. Biotechnol., 2010, 28, 444-445.
24. Rai, A.J. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays. Expert Rev. Mol. Diagn., 2007, 7, 545-553.
25. Javitt, D.C.; Spencer, K.M.; Thaker, G.K.; Winterer, G.; Hajós, M. Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov., 2008, 7, 68-83.
26. Yang, S.Y.; Adelstein, J.; Kassis, A.I. Putative molecular signatures for the imaging of prostate cancer. Expert Rev. Mol. Diagn., 2010, 10, 65-74.
27. Willmann, J.K.; van Bruggen, N.; Dinkelborg, L.M. Gambhir, S.S. Molecular imaging in drug development. Nat Rev Drug Discov., 2008, 7, 591-607.
28. Polanski, M.; Anderson, N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights, 2007, 1, 1-48.
29. Bayés, A.; Grant, S.G. Neuroproteomics: understanding the molecular organization and complexity of the brain. Nat. Rev. Neurosci., 2009, 10, 635-646.
30. Amacher, D.E. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol., 2010, 245, 134-142.
31. Gao, Y.; Holland, R.D.; Yu, L.R. Quantitative proteomics for drug toxicity. Brief. Funct. Genomic. Proteomic., 2009, 8, 158-166.
32. Celis, J.E.; Gromov, P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell, 2003, 3, 9-15.
33. Sakai, J.; Ishikawa, H.; Satoh, H.; Yamamoto, S.; Kojima, S.; Kanaoka, M. Two-dimensional differential gel electrophoresis of rat heart proteins in ischemia and ischemia-reperfusion. Methods Mol. Biol., 2007, 357, 33-43.
34. Poon, T.C. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics, 2007, 4, 51-65.
35. Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. Nature, 2003, 422, 198-207.
36. Smith, L.; Watson, M.B.; O'Kane, S.L.; Drew, P.J.; Lind, M.J.; Cawkwell, L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther., 2006, 5, 2115-2120.
37. Findeisen, P.; Neumaier, M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev. Proteomics, 2009, 6, 457-459.
38. Motoyama, A.; Yates, J.R. 3rd. Multidimensional LC separations in shotgun proteomics. Anal. Chem., 2008, 80, 7187-7193.
39. Adachi, J.; Kumar, C.; Zhang, Y.; Olsen, J.V.; Mann, M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol., 2006, 7, R80.
40. Zougman, A.; Pilch, B.; Podtelejnikov, A.; Kiehntopf, M.; Schnabel, C.; Kumar, C.; Mann, M. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res., 2008, 7, 386-399.
41. Collier, T.S.; Sarkar, P.; Franck, W.L.; Rao, B.M.; Dean, R.A.; Muddiman, D.C. Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. Anal Chem., 2010, 82, 8696-8702.
42. Martins-de-Souza, D.; Maccarrone, G.; Wobrock, T.; Zerr, I.; Gormanns, P.; Reckow, S.; Falkai, P.; Schmitt, A.; Turck, C.W. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res., 2010, 44, 1176-1189.
43. Martins-de-Souza, D.; Harris, L.W.; Guest, P.C.; Turck, C.W.; Bahn, S. The role of proteomics in depression research. Eur. Arch. Psychiatry Clin. Neurosci., 2010, 260, 499-506.
44. Zhou, A.; Zhang, F.; Chen, J.Y. PEPPI: a peptidomic database of human protein isoforms for proteomics experiments. BMC Bioinformatics., 2010, 11(Suppl. 6), S7.
45. Lixia, M.; Zhijian, C.; Chao, S.; Chaojiang, G.; Congyi, Z. Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J. Biochem. Mol. Biol., 2007, 40, 15-21.
46. Venables, J.P.; Klinck, R.; Bramard, A.; Inkel, L.; Dufresne-Martin, G.; Koh, C.; Gervais-Bird, J.; Lapointe, E.; Froehlich, U.; Durand, M.; Gendron, D.; Brosseau, J.P.; Thibault, P.; Lucier, J.F.; Tremblay, K.; Prinos, P.; Wellinger, R.J.; Chabot, B.; Rancourt, C.; Elela, S.A. Identification of alternative splicing markers for breast cancer. Cancer Res., 2008, 68, 9525-9531.
47. Baenziger, J.U. A major step on the road to understanding a unique posttranslational modification and its role in a genetic disease. Cell, 2003, 113, 421-422.
48. Gyorgy, B.; Toth, E.; Tarcsa, E.; Falus, A.; Buzas, E.I. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell Biol., 2006, 38, 1662-1677.
49. Schiess, R.; Wollscheid, B.; Aebersold, R. Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol., 2009, 3, 33-44.
50. Doerr, A. Targeted proteomics. Nat. Methods, 2010, 7, 34.
51. Yang, X.; Lazar, I.M. MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer, 2009, 9, 96.
52. Pan, S.; Aebersold, R.; Chen, R.; Rush, J.; Goodlett, D.R.; McIntosh, M.W.; Zhang, J.; Brentnall, T.A. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res., 2009, 8, 787-797.
53. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics, 2007, 6, 2212-2229.
54. Stahl-Zeng, J.; Lange, V.; Ossola, R.; Eckhardt, K.; Krek, W.; Aebersold, R.; Domon, B. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics, 2007, 6, 1809-1817.
55. Lange, V.; Malmström, J.A.; Didion, J.; King, N.L.; Johansson, B.P.; Schäfer, J.; Rameseder, J.; Wong, C.H.; Deutsch, E.W.; Brusniak, M.Y.; Bühlmann, P.; Björck, L.; Domon, B.; Aebersold, R. Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol. Cell. Proteomics, 2008, 7, 1489-1500.
56. Picotti, P.; Bodenmiller, B.; Mueller, L.N.; Domon, B.; Aebersold, R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell, 2009, 138, 795-806.
57. El-Houseini, M.E.; Mohammed, M.S.; Elshemey, W.M.; Hussein, T.D.; Desouky, O.S.; Elsayed, A.A. Enhanced detection of hepatocellular carcinoma. Cancer Control, 2005, 12, 248-253.
58. van der Greef, J.; Adourian, A.; Muntendam, P.; McBurney, R.N. Lost in translation? Role of metabolomics in solving translational problems in drug discovery and development. Drug Discovery Today: Technologies, 2006, 3, 205-211.
59. van der Greef, J.; Hankemeier, T.; McBurney, R.N. Metabolomicsbased systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics, 2006, 7, 1087-1094.
60. Rossing, K.; Mischak, H.; Dakn, a M.; Zürbig, P.; Novak, J.; Julian, B.A.; Good, D.M.; Coon, J.J.; Tarnow, L.; Rossing, P.; PREDICTIONS Network. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol., 2008, 19, 1283-1290.
61. Morel, N.M.; Holland, J.M.; van der Greef, J.; Marple, E.W.; Clish, C.; Loscalzo, J.; Naylor, S. Primer on medical genomics. Part XIV: Introduction to systems biology--a new approach to understanding disease and treatment. Mayo Clin. Proc., 2004, 79, 651-658.
62. van der Greef, J.; Martin, S.; Juhasz, P.; Adourian, A.; Plasterer, T.; Verheij, E.R.; McBurney, R.N. The art and practice of systems biology in medicine: mapping patterns of relationships. J. Proteome Res., 2007, 6, 1540-1559.
63. Anderson, N.L.; Anderson, N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics, 2002, 1, 845-867.
64. Hortin, G.L.; Jortani, S.A.; Ritchie, J.C. Jr.; Valdes, R. Jr.; Chan, D.W. Proteomics: a new diagnostic frontier. Clin. Chem., 2006, 52, 1218-1222.
65. Hortin, G.L.; Sviridov, D. The dynamic range problem in the analysis of the plasma proteome. J. Proteomics, 2010, 73, 629-636.
66. Travis, J.; Bowen, J.; Tewksbury, D.; Johnson, D.; Pannell, R. Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. Biochem. J., 1976, 157, 301-306.
67. Ahmed, N.; Barker, G.; Oliva, K.; Garfin, D.; Talmadge, K.; Georgiou, H.; Quinn, M.; Rice, G. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics, 2003, 3, 1980-1987.
68. Shaw, M.M.; Riederer, B.M. Sample preparation for twodimensional gel electrophoresis. Proteomics, 2003, 3, 1408-1417.
69. Li, C.; Lee, K.H. Affinity depletion of albumin from human cerebrospinal fluid using Cibacron-blue-3G-A-derivatized photopatterned copolymer in a microfluidic device. Anal. Biochem., 2004, 333, 381-388.
70. Greenough, C.; Jenkins, R.E.; Kitteringham, N.R.; Pirmohamed, M.; Park, B.K.; Pennington, S.R. A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics, 2004, 4, 3107-3111.
71. Wang, Y. Y,; Cheng, P.; Chan, D.W. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics, 2003, 3, 243-248.
72. Björhall, K.; Miliotis, T.; Davidsson, P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics, 2005, 5, 307-317.
73. Omenn, G.S.; States, D.J.; Adamski, M.; Blackwell, T.W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B.B.; Simpson, R.J.; Eddes, J.S.; Kapp, E.A.; Moritz, R.L.; Chan, D.W.; Rai, A.J.; Admon, A.; Aebersold, R.; Eng, J.; Hancock, W.S.; Hefta, S.A.; Meyer, H.; Paik, Y.K.; Yoo, J.S.; Ping, P.; Pounds, J.; Adkins, J.; Qian, X.; Wang, R.; Wasinger, V.; Wu, C.Y.; Zhao, X.; Zeng, R.; Archakov, A.; Tsugita, A.; Beer, I.; Pandey, A.; Pisano, M.; Andrews, P.; Tammen, H.; Speicher, D.W.; Hanash, S.M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics, 2005, 5, 3226-3245.
74. Tirumalai, R.S.; Chan, K.C.; Prieto, D.A.; Issaq, H.J.; Conrads, T.P.; Veenstra, T.D. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics, 2003, 2, 1096-1103.
75. States, D.J.; Omenn, G.S.; Blackwell, T.W.; Fermin, D.; Eng, J.; Speicher, D.W.; Hanash, S.M. Challenges in deriving highconfidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol., 2006, 24, 333-338.
76. Schenk, S.; Schoenhals, G.J.; de Souza, G.; Mann, M. A high confidence, manually validated human blood plasma protein reference set. BMC Med. Genomics, 2008, 1, 41.
77. Tucholska, M.; Bowden, P.; Jacks, K.; Zhu, P.; Furesz, S.; Dumbrovsky, M.; Marshall, J. Human serum proteins fractionated by preparative partition chromatography prior to LC-ESI-MS/MS. J. Proteome Res., 2009, 8, 1143-1155.
78. Williams, D.K.; Muddiman, D.C. Absolute quantification of Creactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J. Proteome Res., 2009, 8, 1085-1090.
79. Fortin, T.; Salvador, A.; Charrier, J.P.; Lenz, C.; Lacoux, X.; Morla, A, Choquet-Kastylevsky, G.; Lemoine, J. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics, 2009, 8, 1006-1015.
80. Fortin, T.; Salvador, A.; Charrier, J.P.; Lenz, C.; Bettsworth, F.; Lacoux, X.; Choquet-Kastylevsky, G.; Lemoine, J. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem., 2009, 81, 9343-9452.
81. Simpson, R.J.; Lim, J.W.; Moritz, R.L.; Mathivanan, S. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics, 2009, 6, 267-283.
82. Pisitkun, T.; Shen, R.F.; Knepper, M.A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA, 2004, 101, 13368-13373.
83. Gonzales, P.A.; Pisitkun, T.; Hoffert, J.D.; Tchapyjnikov, D.; Star, R.A.; Kleta, R.; Wang, N.S.; Knepper, M.A. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol., 2009, 20, 363-379.
84. Muller, P.Y.; Dieterle, F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin. Drug Metab. Toxicol., 2009, 5, 1023-1038.
85. Ozer, J.S. A guidance for renal biomarker lead optimization and use in translational pharmacodynamics. Drug Discov. Today, 2010, 15, 142-147.
86. Tesch, G.; Amur, S.; Schousboe, J.T.; Siegel, J.N.; Lesko, L.J.; Bai, J.P. Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J., 2010, 12, 243-253.
87. Perkins, B.A.; Ficociello, L.H.; Silva, K.H.; Finkelstein, D.M.; Warram, J.H.; Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med., 2003, 348, 2285-2293.
88. Russo, L.M.; Sandoval, R.M.; Campos, S.B.; Molitoris, B.A.; Comper, W.D.; Brown, D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J. Am. Soc. Nephrol., 2009, 20, 489-494.
89. Comper, W.D.; Hilliard, L.M.; Nikolic-Paterson, D.J.; Russo, L.M. Disease-dependent mechanisms of albuminuria. Am. J. Physiol. Renal Physiol., 2008, 295, F1589-1600.
90. Thompson, E.J.; Keir, G. Laboratory investigation of cerebrospinal fluid proteins. Ann. Clin. Biochem., 1990, 27, 425-435.
91. Suk, K. Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. Expert Rev. Proteomics., 2010, 7, 263-274.
92. Maurer, M.H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom. Rev., 2010, 29, 17-28.
93. Huang, J.T.; McKenna, T.; Hughes, C.; Leweke, F.M.; Schwarz, E.; Bahn, S. CSF biomarker discovery using label-free nano-LCMS based proteomic profiling: technical aspects. J. Sep. Sci., 2007, 30, 214-225.
94. Schwarz, E.; Bahn, S. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Rev. Mol. Diagn., 2008, 8, 209-216.
95. Seehusen, D.A.; Reeves, M.M.; Fomin, D.A. Cerebrospinal fluid analysis. Am. Fam. Physician, 2003, 68, 1103-1108.
96. Shaw, L.M.; Vanderstichele, H.; Knapik-Czajka, M.; Clark, C.M.; Aisen, P.S.; Petersen, R.C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; Dean, R.; Siemers, E.; Potter, W.; Lee, V.M.; Trojanowski, J.Q. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol., 2009, 65, 403-413.
97. Zhang, J.; Sokal, I.; Peskind, E.R.; Quinn, J.F.; Jankovic, J.; Kenney, C.; Chung, K.A.; Millard, S.P.; Nutt, J.G.; Montine, T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol., 2008, 129, 526-529.
98. Yin, G.N.; Lee, H.W.; Cho, J.Y.; Suk, K; Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res., 2009, 1265, 158-170.
99. Zhang, J.; Goodlett, D.R.; Quinn, J.F.; Peskind, E.; Kaye, J.A.; Zhou, Y.; Pan, C.; Yi, E.; Eng, J.; Wang, Q.; Aebersold, R.H.; Montine, T.J. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis., 2005, 7, 125-133.
100. Straten, G.; Eschweiler, G.W.; Maetzler, W.; Laske, C.; Leyhe, T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J. Alzheimers Dis., 2009, 18, 331-337.
101. Eller, M.; Williams, D.R. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol., 2009, 5, 561-570.
102. Abdi, F.; Quinn, J.F.; Jankovic, J.; McIntosh, M.; Leverenz, J.B.; Peskind, E.; Nixon, R.; Nutt, J.; Chung, K.; Zabetian, C.; Samii, A.; Lin, M.; Hattan, S.; Pan, C.; Wang, Y.; Jin, J.; Zhu, D.; Li, G.J.; Liu, Y.; Waichunas, D.; Montine, T.J.; Zhang, J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis., 2006, 9, 293-348.
103. Mitchell, R.M.; Freeman, W.M.; Randazzo, W.T.; Stephens, H.E.; Beard, J.L.; Simmons, Z.; Connor, JR. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology, 2009, 72, 14-19.
104. Pasinetti, G.M.; Ungar, L.H.; Lange, D.J.; Yemul, S.; Deng, H.; Yuan, X.; Brown, R.H.; Cudkowicz, M.E.; Newhall, K.; Peskind, E.; Marcus, S.; Ho, L. Identification of potential CSF biomarkers in ALS. Neurology, 2006, 66, 1218-1222.
105. Brechlin, P.; Jahn, O.; Steinacker, P.; Cepek, L.; Kratzin, H.; Lehnert, S.; Jesse, S.; Mollenhauer, B.; Kretzschmar, H.A.; Wiltfang, J.; Otto, M. Cerebrospinal fluid-optimized twodimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics, 2008, 8, 4357-4366.
106. O'Connor, K.C.; Roy, S.M.; Becker, C.H.; Hafler, D.A.; Kantor, A.B. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis. Markers, 2006, 22, 213-225.
107. Qin, Z.; Qin, Y.; Liu, S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol., 2009, 29, 203-210.
108. Kaddurah-Daouk, R.; Kristal, B.S.; Weinshilboum, R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 653-683.
109. Lindon, J.C.; Holmes, E.; Nicholson, J.K. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn., 2004, 4, 189-199.
110. Hollywood, K.; Brison, D.R.; Goodacre, R. Metabolomics: current technologies and future trends. Proteomics, 2006, 6, 4716-4723.
111. Weckwerth, W.; Morgenthal, K. Metabolomics: from pattern recognition to biological interpretation. Drug Discov. Today, 2005, 10, 1551-1558.
112. Wishart, D.S. Applications of metabolomics in drug discovery and development. Drugs R. D., 2008, 9, 307-322.
113. van der Greef, J.; McBurney, R.N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov., 2005, 4, 961-967.
114. Duarte, N.C.; Herrgård, M.J.; Palsson, B. Ø. Reconstruction and validation of Saccharomyces cerevisiae iND750, a fully compartmentalized genome-scale metabolic model. Genome Res., 2004, 14, 1298-1309.
115. Romero, P.; Wagg, J.; Green, M.L.; Kaiser, D.; Krummenacker, M.; Karp, P.D. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol., 2005, 6, R2.
116. Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M.A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.; Amegbey, G.; Block, D.; Hau, D.D.; Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G.E.; Macinnis, G.D.; Weljie, A.M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner, R.; Li, L.; Marrie, T.; Sykes, B.D.; Vogel, H.J.; Querengesser, L. HMDB: the Human Metabolome Database. Nucleic Acids Res., 2007, 35, D521-526.
117. Wishart, D.S.; Knox, C.; Guo, A.C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D.D.; Psychogios, N.; Dong, E.; Bouatra, S.; Mandal, R.; Sinelnikov, I.; Xia, J.; Jia, L.; Cruz, J.A.; Lim, E.; Sobsey, C.A.; Shrivastava, S.; Huang, P.; Liu, P.; Fang, L.; Peng, J.; Fradette, R.; Cheng, D.; Tzur, D.; Clements, M.; Lewis, A.; De Souza, A.; Zuniga, A.; Dawe, M.; Xiong, Y.; Clive, D.; Greiner, R.; Nazyrova, A.; Shaykhutdinov, R.; Li, L.; Vogel, H.J.; Forsythe, I. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res., 2009, 37, D603-610.
118. Han, X.; Gross, R.W. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res., 2003, 44, 1071-1079.
119. Taguchi, R.; Nishijima, M.; Shimizu, T. Basic analytical systems for lipidomics by mass spectrometry in Japan. Methods Enzymol., 2007, 432, 185-211.
120. Ejsing, C.S.; Sampaio, J.L.; Surendranath, V.; Duchoslav, E.; Ekroos, K.; Klemm, R.W.; Simons, K.; Shevchenko, A. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc. Natl. Acad. Sci. USA., 2009, 106, 2136-2141.
121. Hu, C.; van der Heijden, R.; Wang, M.; van der Greef, J.; Hankemeier, T.; Xu, G. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877, 2836-2846.
122. Piomelli, D.; Astarita, G.; Rapaka, R. A neuroscientist's guide to lipidomics. Nat. Rev. Neurosci., 2007, 8, 743-754.
123. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 123-150.
124. Lindon, J.C.; Holmes, E.; Nicholson, J.K. Metabonomics in pharmaceutical R&D. FEBS J., 2007, 274, 1140-1151.
125. Keun, H.C.; Ebbels, T.M.; Antti, H.; Bollard, M.E.; Beckonert, O.; Schlotterbeck, G.; Senn, H.; Niederhauser, U.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. Analytical reproducibility in (1)H NMRbased metabonomic urinalysis. Chem. Res. Toxicol., 2002, 15, 1380-1386.
126. 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal. Chem., 2006, 78, 2199-2208.
127. Motta, A.; Paris, D.; Melck, D. Monitoring real-time metabolism of living cells by fast two-dimensional NMR spectroscopy. Anal. Chem., 2010, 82, 2405-2411.
128. Kuhara, T. Gas chromatographic-mass spectrometric urinary metabolome analysis to study mutations of inborn errors of metabolism. Mass Spectrom. Rev., 2005, 24, 814-827.
129. Ji, Y.; Hebbring, S.; Zhu, H.; Jenkins, G.D.; Biernacka, J.; Snyder, K.; Drews, M.; Fiehn, O.; Zeng, Z.; Schaid, D.; Mrazek, D.A.; Kaddurah-Daouk, R.; Weinshilboum, R.M. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther., 2011, 89, 97-104.
130. Monton, M.R.; Soga, T. Metabolome analysis by capillary electrophoresis-mass spectrometry. J. Chromatogr. A., 2007, 1168, 237-246
131. Ramautar, R.; Somsen, G.W.; de Jong, G.J. CE-MS in metabolomics. Electrophoresis, 2009, 30, 276-291.
132. Ohashi, Y.; Hirayama, A.; Ishikawa, T.; Nakamura, S.; Shimizu, K.; Ueno, Y.; Tomita, M.; Soga, T. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol. Biosyst., 2008, 4, 135-147.
133. Sugimoto, M.; Wong, D.T.; Hirayama, A.; Soga, T.; Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics, 2010, 6, 78-95.
134. Soga, T.; Baran, R.; Suematsu, M.; Ueno, Y.; Ikeda, S.; Sakurakawa, T.; Kakazu, Y.; Ishikawa, T.; Robert, M.; Nishioka, T.; Tomita, M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem., 2006, 281, 16768-16776.
135. Coulier, L.; Bas, R.; Jespersen, S.; Verheij, E.; van der Werf, M.J.; Hankemeier, T. Simultaneous quantitative analysis of metabolites using ion-pair liquid chromatography-electrospray ionization mass spectrometry. Anal. Chem., 2006, 78, 6573-6582.
136. Yoshida, H.; Mizukoshi, T.; Hirayama, K.; Miyano, H. Comprehensive analytical method for the determination of hydrophilic metabolites by high-performance liquid chromatography and mass spectrometry. J. Agric. Food Chem., 2007, 55, 551-560.
137. Castro-Perez, J.M.; Kamphorst, J.; DeGroot, J.; Lafeber, F.; Goshawk, J.; Yu, K.; Shockcor, J.P.; Vreeken, R.J.; Hankemeier, T. Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res., 2010, 9, 2377-2389.
138. Bajad, S.U.; Lu, W.; Kimball, E.H.; Yuan, J.; Peterson, C.; Rabinowitz, J.D. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatographytandem mass spectrometry. J. Chromatogr A., 2006, 1125, 76-88.
139. Lu, W.; Bennett, B.D.; Rabinowitz, J.D. Analytical strategies for LC-MS-based targeted metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 871, 236-242.
140. Zhang, X.; Rauch, A.; Xiao, H.; Rainer, G.; Logothetis, N.K. Mass spectrometry-based neurochemical analysis: perspectives for primate research. Expert Rev. Proteomics, 2008, 5, 641-652.
141. Kiefer, P.; Portais, J.C.; Vorholt, J.A. Quantitative metabolome analysis using liquid chromatography-high-resolution mass spectrometry. Anal. Biochem., 2008, 382, 94-100.
142. Southam, A.D.; Payne, T.G.; Cooper, H.J.; Arvanitis, T.N.; Viant, M.R. Dynamic range and mass accuracy of wide-scan direct infusion nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry-based metabolomics increased by the spectral stitching method. Anal Chem., 2007, 79, 4595-4602.
143. Han, J.; Danell, R.M.; Patel, J.R.; Gumerov, D.R. Scarlett, C.O.; Speir, J.P.; Parker, C.E.; Rusyn, I.; Zeisel, S.; Borchers, C.H. Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry. Metabolomics, 2008, 4(2), 128-140.
144. Shvartsburg, A.A.; Danielson, W.F.; Smith, R.D. High-resolution differential ion mobility separations using helium-rich gases. Anal. Chem., 2010, 82, 2456-246
145. Kuhara, T. Noninvasive human metabolome analysis for differential diagnosis of inborn errors of metabolism. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 855, 42-50.
146. Kuhara, T. Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 781, 497-517.
147. Bryan, D.T. GC-MS and pyrimidine metabolism. Modern Drug Discovery, 2001, 4(9), 15.
148. Randall, C.W. Diagnosing Newborns. Modern Drug Discovery, 2002, 5(4), 29-33.
149. Kuhara, T.; Ohdoi, C.; Ohse, M. Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects. J. Chromatogr. B Biomed. Sci. Appl., 2001, 758, 61-74.
150. Holmes, E.; Loo, R.L.; Stamler, J.; Bictash, M.; Yap, I.K.; Chan, Q.; Ebbels, T.; De Iorio, M.; Brown, I.J.; Veselkov, K.A.; Daviglus, M.L.; Kesteloot, H.; Ueshima, H.; Zhao, L.; Nicholson, J.K.; Elliott, P. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature, 2008, 453, 396-400.
151. Frye, R.F.; Matzke, G.R.; Adedoyin, A.; Porter, J.A.; Branch, R.A. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther., 1997, 62, 365-376.
152. van Wietmarschen, H.; Yuan, K.; Lu, C.; Gao, P.; Wang, J.; Xiao, C.; Yan, X.; Wang, M.; Schroën, J.; Lu, A.; Xu, G.; van der Greef, J. Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J. Clin. Rheumatol., 2009, 15, 330-337.
153. Verpoorte, R.; Crommelin, D.; Danhof, M.; Gilissen, L.J.; Schuitmaker, H.; van der Greef, J.; Witkamp, R.F. Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". J. Ethnopharmacol., 2009, 121, 479-481.
154. Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P.; Cao, Q.; Yu J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y.; Nyati, M.K.; Ahsan, A.; Kalyana-Sundaram, S.; Han, B.; Cao, X.; Byun, J.; Omenn, G.S.; Ghosh, D.; Pennathur, S.; Alexander, D.C.; Berger, A.; Shuster, J.R.; Wei, J.T.; Varambally, S.; Beecher, C.; Chinnaiyan, A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.
155. Wang, J.; Alexander, P.; Wu, L.; Hammer, R.; Cleaver, O.; McKnight, S.L. Dependence of mouse embryonic stem cells on threonine catabolism. Science, 2009, 325, 435-439.
156. Witzmann, F.A.; Li, J. Proteomics and nephrotoxicity. Contrib. Nephrol., 2004, 141, 104-123.
157. Espandiari, P.; Zhang, J.; Rosenzweig, B.A.; Vaidya, V.S.; Sun, J.; Schnackenberg, L.; Herman, E.H.; Knapton, A.; Bonventre, J.V.; Beger, R.D.; Thompson, K.L.; Hanig, J. The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol. Sci., 2007, 99, 637-648.
158. Zhou, Y.; Vaidya, V.S.; Brown, R.P.; Zhang, J.; Rosenzweig, B.A.; Thompson, K.L.; Miller, T. J; Bonventre, J.V.; Goering, P.L. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol. Sci., 2008, 101, 159-170.
159. Goodsaid, F.M.; Blank, M.; Dieterle, F.; Harlow, P.; Hausner, E.; Sistare, F.; Thompson, A.; Vonderscher, J. Novel biomarkers of acute kidney toxicity. Clin. Pharmacol. Ther., 2009, 86, 490-496.
160. Dieterle, F.; Sistare, F.; Goodsaid, F.; Papaluca, M.; Ozer, J.S.; Webb, C.P.; Baer, W.; Senagore, A.; Schipper, M.J.; Vonderscher, J.; Sultana, S.; Gerhold, D.L.; Phillips, J.A.; Maurer, G.; Carl, K.; Laurie, D.; Harpur, E.; Sonee, M.; Ennulat, D.; Holder, D.; Andrews-Cleavenger, D.; Gu, Y.Z.; Thompson, K.L.; Goering, P.L.; Vidal, J.M.; Abadie, E.; Maciulaitis, R.; Jacobson-Kram, D.; Defelice, A.F.; Hausner, E.A.; Blank, M.; Thompson, A.; Harlow, P.; Throckmorton, D.; Xiao, S.; Xu, N.; Taylor, W.; Vamvakas, S.; Flamion, B.; Lima, B.S.; Kasper, P.; Pasanen, M.; Prasad, K.; Troth, S.; Bounous, D.; Robinson-Gravatt, D.; Betton, G.; Davis, M.A.; Akunda, J.; McDuffie, J.E.; Suter, L.; Obert, L.; Guffroy, M.; Pinches, M.; Jayadev, S.; Blomme, E.A.; Beushausen, S.A.; Barlow, V.G.; Collins, N.; Waring, J.; Honor, D.; Snook, S.; Lee, J.; Rossi, P.; Walker, E.; Mattes, W. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol., 2010, 28, 455-462.
161. Han, W.K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J.V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int., 2002, 62, 237-244.
162. Vaidya, V.S.; Ramirez, V.; Ichimura, T.; Bobadilla, N.A.; Bonventre, J.V. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol., 2006, 290, F517-529.
163. Mishra, J.; Mori, K.; Ma, Q.; Kelly, C.; Barasch, J.; Devarajan, P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol., 2004, 24, 307-315.
164. Mishra, J.; Dent, C.; Tarabishi, R.; Mitsnefes, M.M.; Ma, Q.; Kelly, C.; Ruff, S.M.; Zahedi, K.; Shao, M.; Bean, J.; Mori, K.; Barasch, J.; Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005, 365, 1231-1238.
165. Han, W.K.; Waikar, S.S.; Johnson, A.; Betensky, R.A.; Dent, C.L.; Devarajan, P.; Bonventre, J.V. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008, 73, 863-869.
166. Williams, R.E.; Major, H.; Lock, E.A.; Lenz, E.M.; Wilson, I.D. DSerine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology, 2005, 207, 179-190.
167. 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers, 2005, 10, 173-187.
168. 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst, 2004, 129, 535-541.
169. Lindon, J.C.; Holmes, E.; Bollard, M.E.; Stanley, E.G.; Nicholson, J.K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers, 2004, 9, 1-31.
170. Bateman, R.J.; Munsell, L.Y.; Morris, J.C.; Swarm, R.; Yarasheski, K.E.; Holtzman, D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med., 2006, 12, 856-861.
171. Bateman, R.J.; Munsell, L.Y.; Chen, X.; Holtzman, D.M.; Yarasheski, K.E. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J. Am. Soc. Mass Spectrom., 2007, 18, 997-1006.
172. Bateman, R.J.; Siemers, E.R.; Mawuenyega, K.G.; Wen, G.; Browning, K.R.; Sigurdson, W.C.; Yarasheski, K.E.; Friedrich, S.W.; Demattos, R.B.; May, P.C.; Paul, S.M.; Holtzman, D.M. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol., 2009, 66, 48-54.
173. Cook, J.J.; Wildsmith, K.R.; Gilberto, D.B.; Holahan, M.A.; Kinney, G.G.; Mathers, P.D.; Michener, M.S.; Price, E.A.; Shearman, M.S.; Simon, A.J.; Wang, J.X.; Wu, G.; Yarasheski, K.E.; Bateman, R.J. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J. Neurosci., 2010, 30, 6743-6750.
174. Bren, L. Metabolomics: working toward personalized medicine. FDA Consum., 2005, 39, 28-33.
175. Gonzalez-Angulo, A.M.; Hennessy, B.T.; Mills, G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol., 2010, 28, 2777-2783.
176. Clayton, T.A.; Baker, D.; Lindon, J.C.; Everett J.R.; Nicholson J.K. Pharmacometabonomic identification of a significant host microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA, 2009, 106, 14728-14733.
177. Minami, Y.; Kasukawa, T.; Kakazu, Y.; Iigo, M.; Sugimoto, M.; Ikeda, S.; Yasui, A.; van der Horst, G.T.; Soga, T.; Ueda, H.R. Measurement of internal body time by blood metabolomics. Proc. Natl. Acad. Sci. USA, 2009, 106, 9890-9895.
178. st century. Mcgill. J. Med., 2007, 10, 53-57.